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ABSTRACT
Objective In this systematic review, we aimed to 
summarise the empirical evidence on common mental 
disorders (CMDs), cognitive impairment, frailty and health- 
related quality of life (HRQoL) among people living with 
HIV aged ≥50 years (PLWH50 +) residing in sub- Saharan 
Africa (SSA). Specifically, we document the prevalence and 
correlates of these outcomes.
Design, data sources and eligibility criteria The 
following online databases were systematically searched: 
PubMed, CINAHL, PsycINFO, Embase and Scopus up 
to January 2021. English- language publications on 
depression, anxiety, cognitive function, frailty and quality of 
life among PLWH50 + residing in SSA were included.
Data extraction and synthesis We extracted information, 
including study characteristics and main findings. These 
were tabulated, and a narrative synthesis approach was 
adopted, given the substantial heterogeneity among 
included studies.
Results A total of 50 studies from fifteen SSA countries 
met the inclusion criteria. About two- thirds of these studies 
emanated from Ethiopia, Uganda and South Africa. Studies 
regarding depression predominated (n=26), followed by 
cognitive impairment (n=13). Overall, PLWH50 + exhibited 
varying prevalence of depression (6%–59%), cognitive 
impairments (4%–61%) and frailty (3%–15%). The correlates 
of CMDs, cognitive impairment, frailty and HRQoL were rarely 
investigated, but those reported were sociodemographic 
variables, many of which were inconsistent.
Conclusions This review documented an increasing 
number of published studies on HIV and ageing from 
SSA. However, the current evidence on the mental 
and well- being outcomes in PLWH50 + is inadequate 
to characterise the public health dimension of these 
impairments in SSA, because of heterogeneous findings, 
few well- designed studies and substantial methodological 
limitations in many of the available studies. Future work 
should have sufficiently large samples of PLWH50+, 
engage appropriate comparison groups, harmonise the 
measurement of these outcomes using a standardised 
methodology to generate more robust prevalence 
estimates and confirm predictors.
PROSPERO registration number CRD42020145791.
BACKGROUND
All societies globally are experiencing an 
ageing population—some are in its early 
stages, and some are more advanced.1 
Likewise, the proportion of people living with 
HIV (PLWH) aged ≥50 years (considered 
as older adults within the HIV literature) is 
growing rapidly across the globe,2 demanding 
an increase in research, policy and practice to 
address the complex needs of this vulnerable 
group.3 In 2016, there were around 6 million 
PLWH50 + globally, representing 16% of the 
entire adult HIV population.2 This propor-
tion was projected to reach 21% by the end 
of 2020, with Southern and Eastern Africa 
containing the vast majority of PLWH50+.2 
The increase in older PLWH is mainly driven 
by two factors: effective antiretroviral therapy 
(ART) and new HIV infections among the 
elderly.4
This rapidly growing segment of 
PLWH50 + yields new challenges. Several 
HIV and ageing cohorts (mostly from high- 
income countries, HICs) are pointing out an 
elevated burden of physical conditions (eg, 
cardiometabolic diseases), mental morbid-
ities (eg, depression, cognitive disorders), 
psychosocial challenges (eg, stigma, lone-
liness) and geriatric syndromes (eg, frailty) 
Strengths and limitations of this study
 ► This is the first comprehensive review of common 
mental disorders, cognitive impairment, frailty and 
quality of life among older adults living with HIV in 
sub- Saharan Africa, synthesising the current ev-
idence regarding the prevalence and correlates of 
these outcomes.
 ► Our expanded search of five online databases and 
snowballing techniques minimised the risk of miss-
ing relevant studies.
 ► Meta- analysis was not conducted due to extensive 
heterogeneity across the studies in methods and 
presentation of results.
 ► We observed substantial methodological limitations 
in many of the included studies, for example, small 
sample sizes, making it difficult to characterise the 
real public health dimension of these impairments 
in the region.
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among PLWH ≥50 years (PLWH50+) compared with 
their uninfected counterparts.4–6 Unfortunately, the 
mechanisms for the heightened risk of poor outcomes 
among PLWH50 + are not fully understood but span a 
host of disease- related factors, legacy of the early years of 
the HIV epidemic and host vulnerability factors.4 Frailty, 
common mental disorders (CMDs) such as depression 
and anxiety, and cognitive impairments are of particular 
concern in this population.4–6 Frailty is an important 
emerging indicator of vulnerability that is increasingly 
being evaluated among individuals ageing with HIV.7 It 
describes a state of physiological vulnerability that, in the 
presence of internal or external stressors, puts a person 
at an elevated risk of adverse clinical outcomes, such 
as hospitalisation, functional disability and mortality.8 9 
Overall, mental morbidities and frailty are understudied 
in the literature despite their elevated burden and poten-
tial adverse impacts on HIV treatment and health- related 
quality of life (HRQoL).
Despite the apparent need to sharpen the focus on 
the needs of the growing cohort of PLWH50+, this popu-
lation is being neglected in HIV care and prevention 
efforts, especially in low- income and middle- income 
settings of sub- Saharan Africa (SSA). In SSA, this concern 
is not just based on the close association between ageing 
and physical, cognitive, mental impairments, but also on 
the recognition that older adults are not considered to 
be a priority for policy issues. They are marginalised and 
increasingly vulnerable to greater poverty.10 11 Thus, the 
burden and determinants of physical and mental impair-
ments in these adults in SSA, the region most affected by 
HIV globally, are largely undocumented.12
The course and implication of physical and mental 
morbidities among PLWH50 + are well described in HICs, 
but it is an emergent research area in SSA. However, since 
2010, the SSA region has witnessed a rise in interest in 
HIV and ageing outcomes, evidenced by the establish-
ment of cohort studies of older people in different parts 
of Africa.13–15 This is encouraging since data from HICs 
may not be readily generalised to SSA where differ-
ences in, for example, genetics, social environmental 
milieu, formal and informal support systems will almost 
certainly alter the risk profile and morbidity character-
istics among PLWH50+. Therefore, the current review 
aims to summarise the existing empirical evidence on 
CMDs, cognitive impairment, frailty and HRQoL among 
PLWH50 + in SSA by addressing the following specific 
objectives.
1. Establish the prevalence of CMDs, cognitive impair-
ment and frailty among PLWH50 + in SSA.
2. Identify the correlates of CMDs, cognitive impairment, 
frailty and HRQoL among PLWH50 + in SSA.
METHODS
We followed the Preferred Reporting Items for System-
atic Reviews and Meta- analyses guidelines to report the 
study.16
Search strategy
Five online databases (PubMed, CINAHL, PsycINFO, 
Embase and Scopus) were searched for publications. 
The last search was conducted on 4 January 2021. The 
following search terms were used: (HIV OR HIV-1 OR 
HIV/AIDS OR HIV infections) AND (adult OR older 
adult OR older people OR older individual OR elderly) 
AND (Africa OR sub- Saharan Africa OR Africa South of 
the Sahara) AND (cognitive impairment OR neurocogni-
tive impairment OR neurological complication OR HIV- 
associated neurocognitive disorder OR common mental 
disorder OR depression OR depressive symptoms OR 
depressive disorder OR anxiety OR anxiety disorder OR 
quality of life OR health- related quality of life OR grip 
strength OR hand strength OR frailty). We also searched 
through the reference lists of included articles to access 
additional articles. Details of the full search strategy are 
provided in online supplemental file 1.
Studies were considered eligible if they: (1) involved 
PLWH50 + or had participants whose mean/median age 
was ≥50 years or aggregated their outcomes of interest by 
age (including the ≥50 age category); (2) were conducted 
within SSA; (3) were empirical and published in a peer- 
reviewed journal and (4) reported any of our outcomes of 
interest (CMDs, cognitive impairment, frailty or HRQoL). 
We excluded studies that did not aggregate the outcomes 
of interest by HIV status. We also excluded studies that 
were published in non- English languages. Two of the 
authors (PNM and AM) independently screened the 
titles, abstracts and full articles for eligibility and reached 
consensus.
Data extraction and quality assessment
The two authors (PNM and AM) independently extracted 
the following study characteristics using a similarly 
designed extraction sheet: (1) first author; (2) country 
and the year of publication; (3) sample description; (4) 
how the outcome of interest was measured; (5) results 
reported; (6) key findings on the outcome of interest. 
For studies exclusively carried out among PLWH50+, we 
computed or extracted the reported percentages of the 
relevant outcomes. Similarly, for studies with middle- aged 
participants but whose mean/median age was ≥50 years, 
we also computed or extracted the reported percentages 
for the relevant outcomes for the whole sample. For the 
studies with middle- aged participants (but whose mean/
median age was not at least 50 years), we computed 
percentages for participants who fell within the ≥50 cate-
gory, which was usually provided in the papers. In some 
studies, it was impossible to calculate these percentages. 
Hence, the occurrence of a specific outcome was reported 
in the original effect measure, for example, OR, median 
or mean. Any disagreement between the reviewers during 
data abstraction was also resolved by consensus.
We evaluated the quality of included studies using the 
modified version of the Newcastle- Ottawa Scale.17 The 
scale uses five parameters (sample size, sample repre-
sentativeness, comparability between respondents and 
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non- respondents, ascertainment of the outcome of 
interest, and quality of descriptive statistics reporting) 
to obtain a total score ranging from 0 to 5. A score ≥3 
is considered a low risk of bias, while a score of <3 is 
regarded as a high risk of bias.
Data synthesis and analysis
A narrative synthesis approach was used to compare 
studies and describe the state of evidence on all reported 
outcomes; by describing the effect estimates, for instance, 
proportions, means with SD, and median with their IQRs. 
Where applicable, ranges were used to summarise the 
outcomes of interest reported. A meta- analysis could not 
be done due to a limited number of studies and substan-
tial heterogeneity among studies.
Patient and public involvement statement
The accompanying manuscript is part of broader doctoral 
research work for the first author. During the conceptual 
phase of this work, community engagement through 
meetings with different stakeholders was carried out to 
contextualise the issues of ageing and HIV at the coast of 
Kenya (eg, in terms of priorities and preferences). These 
stakeholders included the Kilifi and Mombasa coun-
ties' departments of Health, subcounty health manage-
ment teams, and hospital management teams of various 
health facilities at the study setting. The research team 
received and incorporated useful feedback from these 
meetings towards the design and implementation of 
the project. It also led to further elaborations regarding 
ongoing community engagement during and after the 
study, including disseminating any work arising from this 
project using these forums and others such as publica-
tions, hospital departmental meetings, patient groups and 
conferences as an essential way to discuss the implications 
of the findings. For this systematic review, patients were 
not involved in the conduct of the study. However, the 
results will be disseminated to the relevant patient groups 
within the HIV clinics through feedback meetings.
RESULTS
Characteristics of included studies
We identified 8741 articles from the 5 online databases 
and an additional 7 citations from snowballing. Of these, 
2693 were duplicates. Hence, we screened 6055 titles and 
abstracts for initial eligibility, out of which 575 articles 
were identified. Full articles were obtained for these cita-
tions, of which 50 met the eligibility criteria (figure 1). The 
eligible studies were conducted between 2006 and 2021 
among 15 SSA countries of Uganda (n=13), South Africa 
(n=12), Ethiopia (n=8), Tanzania (n=5), Nigeria (n=3), 
Cameroon (n=2), Côte d’Ivoire (n=2), Senegal (n=2), 
Kenya (n=2), Botswana (n=1), Zambia (n=1), Malawi 
(n=1), Namibia (n=1), Togo (n=1) and Burkina Faso 
(n=1). However, some of these studies were conducted in 
multiple countries. Figure 2 shows the geographical distri-
bution of these studies across the SSA region. Virtually 
all the included studies were cross- sectional, except one 
that presented data from a randomised trial.18 Eighteen 
studies (36%) analysed baseline or follow- up data of 
different cohort studies.
About two- thirds of the included studies (n=35) 
recruited their HIV infected samples from clinical 
settings.18–52 The rest obtained their samples from the 
general population through household surveys and 
community samples. Additionally, many of the studies 
included samples of PLWH50 + lower than 100 (n=22). 
Overall, the samples of PLWH50 + per study ranged from 
19 to 1048,36 53 while those for HIV uninfected older 
adults ranged from 17 to 4022.22 54
Figure 1 Identification of eligible studies. PLWH, people 
living with HIV; SSA, sub- Saharan Africa.
Figure 2 Geographical distribution of the included studies 
within SSA. SSA, sub- Saharan Africa.
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Common HIV disease markers such as the duration of 
HIV infection, current/nadir CD4 +T cell count, dura-
tion of ART use, viral suppression level among PLWH50 + 
were reported in a few studies. However, there was exten-
sive heterogeneity in how the information was reported 
and the level of detail given. In 42% of the included 
studies, all PLWH50 + were on ART. Six other studies 
included only ART naïve PLWH50+. Among ART users, 
viral suppression was reported in five studies where it was 
documented to range from 73% to 90%. Nadir CD4 +T 
cell count among PLWH50 + was reported in four studies 
where most of the participants (about 60%) had a count 
lower than 200. The duration of HIV infection among 
PLWH50 + ranged from 3.5 to 12 years (among the few 
studies that reported this variable).
Only eight studies examined the health outcomes 
of interest using an exclusively HIV infected older 
sample.25 33 40 45–49 Eighteen other studies used HIV unin-
fected older adults as comparison groups, while the rest 
included HIV infected young adults (the ages varied 
extensively).
Depression and anxiety
Depression was reported in 25 studies, while anxiety was 
reported in two studies. Notably, depression was assessed 
using multiple scales with diverse scoring systems. Six 
of the studies used the 9- item Patient Health Question-
naire (PHQ-9), while a similar number used the Centre 
for Epidemiological Studies Depression scale. Five 
other studies used the Mini International Neuropsychi-
atric Interview (MINI), while the rest utilised a host of 
different scales. On the other hand, anxiety was assessed 
using the Schedule for Clinical Assessment in Psychiatry 
and from clinical records.30 39 Nine of the depression 
studies19 29 44 49 51 55–58 reported major depressive disorders 
(MDD), while the remaining sixteen studies reported 
the prevalence of depressive symptoms. To synthesise 
and report the available evidence, depression (when-
ever used in this review) captures both the depressive 
symptoms (derived from brief screening measures) and 
Major Depressive Disorder (based on structured diag-
nostic interviews, for example, the MINI by specialised 
professionals or trained non- specialised workers). More 
information on this outcome is presented in the online 
supplemental table 1.
Prevalence of depression and anxiety
Overall, the prevalence of depression ranged from 6% 
to 59%. We found no clear pattern of over- reporting 
or under- reporting of depression prevalence in the 
included studies, considering the different cut- offs used. 
For instance, in studies using the PHQ-9, the prevalence 
of depression ranged from 47% to 49% (with a cut- off 
of ≥5) and 16% to 45% when using a cut- off of ≥10. We 
also noted a similar observation when we took the ART 
status of PLWH into account. Specifically, the prevalence 
of depression ranged from 8% to 59% among studies 
whose participants were entirely on ART compared with 
6% to 54% among studies with mixed or naïve PLWH. 
However, studies that used structured interviews such as 
the MINI, Composite International Diagnostic Interview 
(CIDI) and Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM- IV) to assess for depres-
sion were noted to frequently report lower prevalence 
of depression among PLWH50+ (ranging from 6% to 
30%)44 57 compared with studies that used brief screening 
scales such as the PHQ-9 (prevalence ranging from 8% to 
59%).27 59
Of note, eight studies documented higher prevalence 
of depression among PLWH50 + than their comparison 
groups.20 23 27 36 37 43 55 56 On the contrary, 11 studies reported 
a lower prevalence of depression among PLWH50 + 
than their comparison groups.19 24 28 29 31 32 44 50 51 58 59 In 
comparison, three other studies reported minimal or no 
differences in depression between PLWH50 + and their 
comparison groups.34 42 57 In one population- based study 
conducted in rural South Africa, neither diagnosis nor 
treatment of HIV was significantly associated with depres-
sion when compared with being uninfected.54
Anxiety was reported in two studies.30 39 In one of them,39 
PLWH50 + on ART presented with the same proportion 
of anxiety symptoms with HIV uninfected older adults at 
3%. In the other study,30 the prevalence of anxiety disor-
ders among PLWH50 + on ART was 21% compared with 
22% in HIV infected young adults (18–50 years).
Reported correlates of depression
Correlates of depression among PLWH50 + were reported 
only in eight studies.27 28 46 48 51 54 55 58 Among sociodemo-
graphic variables, older age,27 54 declining socioeconomic 
status,55 being unemployed,46 being female,28 58 HIV 
status disclosure48 and urban residency58 were associated 
with an elevated risk of depression while being married, 
employed (full- time or part- time work),54 old age,51 
higher educational attainment48 and belonging to the 
highest wealth quintile28 were associated with reduced 
levels of depression. However, in some studies, house-
hold wealth quintile, education levels,51 and age25 were 
not significant correlates of depression. In other studies, 
being a current/former smoker,46 increasing disability 
scores, decreasing mean handgrip strength, reported 
back pain, not having hypertension,55 HIV stigma48 and 
caregiving (for adult children)58 were significantly asso-
ciated with elevated levels of depression. On the other 
hand, receiving a government grant58 and resilience48 
were significantly associated with reduced levels of 
depression. Details of this data are presented in online 
supplemental table 1.
Cognitive and neurological functioning
These outcomes were reported by 13 studies, as high-
lighted in table 1. Of these, five studies quantified the 
prevalence of HIV- associated neurocognitive disor-
ders (HAND) using different measures,25 35 38 40 49 two 
studies reported findings on dementia21 60 while five 
studies documented findings on cognitive function/
 on O
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impairment.22 33 51 53 61 The remaining study reported 
the proportion of HIV- associated peripheral neuropathy 
among PLWH50+.39
Prevalence estimates of reported outcomes
The prevalence of symptomatic HAND among PLWH50 + 
on ART ranged from 19%38 to 61%.35 Two of the HAND 
studies documented elevated proportions of symptomatic 
HAND among PLWH50 + on ART compared with their 
younger counterparts.35 38 In rural South Africa, Joska et al 
examined the prevalence of dementia and its associations 
in a population survey of 1150 rural elderly participants. 
They found no significant differences in the prevalence 
of dementia between PLWH50+ (86% on ART) and HIV 
uninfected counterparts 18% vs 11%, respectively.60 In a 
different study in rural South Africa, a baseline analysis of 
the Health and Ageing in Africa—A Longitudinal Study 
of an INDEPTH Community (HAALSI), HIV infected 
older adults (64% on ART) registered a lower prevalence 
of cognitive impairment (4%) than their uninfected 
peers (9%).53 In a separate analysis of the same baseline 
data of the HAALSI cohort,61 HIV infected older adults 
scored on average 0.06 (95% CI 0.01 to 0.12) SD units 
higher on a conventional cognitive function measure and 
0.02 (95% CI − 0.07 to 0.04) SD units lower when using 
the Oxford Cognitive Screen- Plus (OCS- Plus) measure 
than their HIV- negative counterparts.
Correlates of cognitive function/impairment
The correlates of cognitive function/impairment were 
reported in seven studies. The key predictors of reduced 
cognitive function were mainly sociodemographic: older 
age (≥50 years),21 40 53 60 living alone,25 being illiterate or 
having low formal education level,25 53 being older at the 
time of HIV diagnosis,25 being female, unmarried and 
having low socioeconomic status53 were associated with 
a higher risk of impairment. However, in some studies, 
the effects of age, education and marital status were not 
significant.25 60 Other correlates of cognitive impairment 
included the presence of depressive symptoms,60 a history 
of cardiovascular conditions53 and a history of falls in the 
past 12 months.33 HIV specific factors (such as nadir CD4 
count, ART use)25 61 and vascular risk factors (such as 
smoking status, body mass index and blood pressure)25 
were not associated with cognitive impairment.
Frailty/grip strength
Prevalence estimates
Frailty was reported in three studies.33 47 62 In the first study, 
a hospital- based cross- sectional study of 145 PLWH50 + 
on ART in Tanzania, frailty assessment was completed 
using three measures (the Fried frailty phenotype 
(FFP), the Clinical Frailty Scale (CFS) and Brief Frailty 
Instrument for Tanzania (B- FIT 2)).47 In this study, the 
authors reported low levels of frailty: 3% (when using the 
FFP method) and 1% (when using the CFS and BFIT-2 
methods). The second study documented a similar prev-
alence of frailty among 292 PLWH50+ (ART status not 
reported) and 322 HIV uninfected peers in rural South 
Africa (15% vs 18%, respectively), using a modified 
version of the FFP.62 In the third study, increasing frailty 
scores were significantly associated with increasing poly-
pharmacy levels in a sample of 411 PLWH50 + on ART 
in Uganda.33 Five other studies18 45 57 63 64 reported mean 
handgrip strength as an indicator of frailty, as shown in 
table 2.
Reported correlates of frailty
The correlates of frailty were reported in two studies. 
Being female, unmarried47 and older47 62 were signifi-
cantly associated with worse frailty scores, and there 
were no associations between inflammatory biomarkers 
with frailty.62 Factors associated with mean handgrip 
strength were reported in four of the studies. In one, HIV 
status was significantly associated with weaker handgrip 
strength.57 In another study, being female and divorced/
widowed were significantly associated with weaker hand-
grip strength, while having a secondary education level 
was significantly associated with better handgrip strength. 
Table 2 gives details of this outcome.
Health-related quality of life
This outcome was reported in eight studies. Three- quarters 
of the studies used the WHO Quality of Life measure to 
assess HRQOL. The overall mean quality of life scores 
(out of 100) ranged from 42 to 83 among PLWH50 + 
on ART. In two studies, PLWH50+ (partially on ART) 
reported better quality of life scores than their uninfected 
counterparts.63 65 In contrast, four other studies reported 
a lower quality of life scores39 41 52 66 among PLWH50 + 
compared with to HIV uninfected older adults or HIV 
infected young adults.
The correlates of quality of life were reported in only 
one study,65 where having some source of income and 
being in the upper two wealth quintiles were significantly 
associated with better quality of life among PLWH50+. 
Additionally, being female and previously married were 
associated with reduced odds of good quality of life in 
PLWH50+. Table 3 gives more details on this outcome.
Overall, a significant number of the included studies 
(about 35%) had a low quality score (≤2 – indicating a 
high risk of bias).19–22 26 29 31 35–41 48 51 66 Specifically, about 
two- thirds of the included studies did not report partici-
pant response rates. Sixteen studies used non- probability 
sampling methods or did not report their sampling 
methods. Close to half of the included studies had 
substantially small samples of PLWH50+ (≤100). Further-
more, a substantial number of studies (about 40%) 
provided scarce information regarding their measures’ 
reliability and validity. Details of the quality assessment of 
all included studies are captured in online supplemental 
table 2.
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DISCUSSION
Summary of main findings
Our review shows that the research on depression, anxiety, 
cognitive function, frailty and HRQoL among PLWH50 + 
in SSA is still scanty and largely concentrated in Uganda, 
South Africa and Ethiopia. Overall, PLWH50 + presented 
with wide- ranging prevalence of depression (6% to 59%), 
cognitive impairment (4% to 61%) and frailty (3%–15%). 
Additionally, the correlates of these outcomes were rarely 
investigated. Nonetheless, those reported were mainly 
sociodemographic variables, many of which were incon-
sistent. We find the current evidence inadequate to 
characterise the real burden and determinants of these 
outcomes in the region, partly because of the limited 
number of well- designed studies, heterogeneous find-
ings, and substantial methodological limitations observed 
in many included studies. Therefore, any policies and 
programmes about the well- being of PLWH50 + in the 
region have been made on the basis of minimal evidence. 
The rising numbers of PLWH50 + in SSA and the poten-
tially elevated burden of age- associated comorbidities in 
this population warrant more research across the region. 
Such data will provide the evidence needed to develop 
appropriate policies, programmes and interventions for 
the successful ageing of PLWH in SSA.
Depression and anxiety
Depression was the most frequently reported outcome in 
about half of the included studies. This finding is consis-
tent with the available literature on HIV, which recognises 
depression as the most commonly occurring psychiatric 
complication in this population.67 However, only two 
studies investigated anxiety, a CMD with a similar preva-
lence to those seen in depression.68 The under investiga-
tion of anxiety disorders is of particular concern because 
accumulating research involving PLWH50 + in HICs has 
documented elevated anxiety levels, as high as 65%.68 
More research is needed on this outcome in the region.
Our review also noted wide- ranging prevalences 
of depression and anxiety. This finding corroborates 
previous review findings on the prevalence of CMDs in 
the region, although in younger HIV populations.69 The 
observed variation could reflect significant contextual 
differences across the SSA region, for example, social 
environmental milieu, healthcare systems, patterns of the 
burden of diseases and mental health resources, which 
are likely to alter the risk profile of these adults.70 It could 
also be attributed to potential differences in study popu-
lations, study participants and the use of diverse measure-
ment tools (including different cut- offs for the same 
measures). Indeed, in the current review, depression was 
assessed using at least 10 different scoring systems with 
diverse cut- off points. Besides, the majority of the studies 
did not provide information on the reliability and validity 
of the tools they used. Hence, it is difficult to draw firm 
conclusions regarding the reliability, validity and appli-
cability of many of the measures used to report this 
outcome. The PHQ-9, for instance, was frequently used to 
report depressive symptoms among the included studies. 
However, most of the studies relied on previous validation 
of the tool, the context of which was not given. A recent 
review examining the validation of brief CMDs screening 
tools in low- income and middle- income countries did not 
support the use of PHQ-9 in these settings. It performed 
poorly in several clinic populations with lower average 
education but performed very well in high literate popu-
lations.71 This is especially an important consideration 
in SSA, where older adults are more likely to have low 
literacy levels. There is a need for rigorous cultural adap-
tation of these instruments to generate accurate epidemi-
ological data that will inform proper intervention work 
among PLWH50 + in SSA.
Hiv-associated cognitive impairment
The neurological involvement in HIV disease progres-
sion remains problematic, even in well- controlled PLWH, 
resulting in poor quality of life. HIV associated cognitive 
impairment is deemed one of the most prevalent comor-
bidities in the era of ART. Ageing with HIV would appear 
to impose a synergistic impact, whereby increased comor-
bidities, such as hypertension, diabetes or depression, 
likely contribute to and maintain HIV- associated cogni-
tive impairment. In HICs, PLWH50 + have consistently 
been shown to have high levels of cognitive impairments, 
as high as 50%. The present review found a wide- ranging 
prevalence of HIV- associated cognitive impairment 
(4%–61%). Our observation is consistent with the avail-
able literature, where the prevalence has been noted 
to vary widely depending on sources used and appears 
dependent on the populations studied, and approaches 
used.72
Brief cognitive screening tools such as the Mini Mental 
State Examination and International HIV Dementia Scale 
(IHDS) were frequently used to document the preva-
lence of cognitive impairment compared with compre-
hensive neuropsychological batteries. While the use of 
the brief screeners in low- resource settings is well under-
stood given the resource gap, researchers should exercise 
caution on the tools they use. Recent reviews evaluating 
brief screening tools for neurocognitive impairment in 
HIV/AIDS have indicated that some of the commonly 
used tools, for example, the IHDS perform poorly, espe-
cially in screening milder cognitive impairments.73 74 
In the current review, information on tool reliability or 
validity was rarely reported. One of the studies reported 
a limited diagnostic accuracy of the IHDS. However, the 
OCS- Plus, one of the most recent screening tools, is prom-
ising. So far, the tool has only been used in South Africa 
among older adults living with HIV, and its initial evalu-
ation yielded excellent construct and external validity.75 
This tool has the potential to address some of the unique 
challenges and gaps facing resource- limited settings in 
screening for HAND, including difficulty in performing 
long test batteries, limited screening tools and a shortage 
of clinical staff.
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Frailty
Only two studies quantified the prevalence of frailty 
among PLWH50+, ranging from 3% to 15%. One of the 
studies was exclusively conducted among PLWH50+, 
yielding a low frequency of frailty (3%). In the other study, 
conducted in rural South Africa, the prevalence of frailty 
was similar between PLWH50 + and their uninfected 
counterparts (15% vs 18%, respectively). This finding 
supports the growing evidence in SSA, which suggest 
that older on effective ART have similar or better health 
profiles than their uninfected counterparts, contrary to 
what has been observed in HICs. At the global stage, the 
frailty prevalence in SSA appears relatively lower than that 
of HICs which ranges from 5% to 29%.76 The population 
reaching older age in many SSA settings may be relatively 
fit/active, still working, which may be true of PLWH, 
potentially favouring better physical health in these indi-
viduals. Nonetheless, given the limited number of studies 
on this outcome in SSA, these findings remain prelimi-
nary and inconclusive and highlight the urgent need for 
more studies to shed more light on these observations.
Health-related quality of life
For some time, HRQoL has emerged as a salient indi-
cator of HIV care and an essential target for HIV- related 
research, aiming to expand the service paradigm 
continuum.77 This new quality of life frontier has been 
proposed as the ‘fourth 90’ to the original ‘90-90-90’ 
testing and treatment target championed by UNAIDS: 
to ensure that 90% of people with viral load suppression 
have good HRQoL.77 In the current review, research 
on HRQoL among PLWH50 + was scanty. Thus, little 
is known on the risk and protective factors of patient- 
reported HRQoL. Further studies should explore the 
independent effects of aging- related conditions such 
as CMDs, cognitive impairments and frailty on HRQoL 
among PLWH50 + in SSA to support healthy ageing even 
in the context of a chronic illness such as HIV infection.
Despite the observed limitations, the evidence of 
better mental health,28 44 50 51 54 58 59 as well as cogni-
tion,53 61 frailty/handgrip strength47 62 63 and quality of 
life,65 among PLWH50 + on ART (mainly among the 
robust studies with low risk of bias) compared with unin-
fected older adults in the current review was striking. 
This observation could be part of an emerging body of 
evidence from SSA showing that the mental and well- 
being outcomes among PLWH are comparable to those 
without HIV. The mechanisms responsible for this obser-
vation are not well established and require further exam-
ination across many settings in SSA. However, it could be 
attributed to a few plausible reasons, including (1) the 
direct impact of ART on viral replication, inflammatory 
pathways and downstream disease pathophysiology, the 
so- called ‘ART advantage’,78 79 (2) a survivorship bias 
among PLWH50 + who access and remain in HIV care 
and (3) beneficial spillover effects of ART programmes 
such as enhanced access to and utilisation of primary care 
services resulting in early identification and management 
of comorbid conditions.79–81 This observation could also 
be related to the fact that PLWH50 + on ART are more 
likely to use biomedical facilities due to better education 
and higher socioeconomic status than their HIV unin-
fected peers. More studies, preferably longitudinal ones, 
will shed more light on this observation. As it stands, 
however, this finding offers an interesting contrast to the 
commonly reported findings from HICs, which generally 
show that PLWH50 + present with worse physical and 
mental health outcomes compared with age- matched 
HIV uninfected people.5 68 82 These findings may suggest 
context- specific differences in the drivers of physical 
and mental outcomes, including the demographic and 
risk factor profile as well as the role of engagement in 
HIV care—among those with and without HIV, espe-
cially when comparing low- income and middle- income to 
HICs. Future studies should explore the extent to which 
HIV programmes could be promoting the well- being of 
PLWH50 + in SSA compared with HIV uninfected older 
adults in the general population who are likely to bear the 
brunt of the prevailing poor health systems and primary 
care systems in the region.
The correlates of mental and well-being outcomes
The correlates of CMDs, cognitive impairment, frailty and 
HRQoL have been scarcely investigated in SSA. In the 
current review, the frequently reported correlates were 
sociodemographic in nature, many of which (eg, age, 
formal education levels and wealth status) were inconsis-
tent. However, being female was consistently associated 
with declining mental health, cognitive function, HRQoL 
and frailty status. This finding mirrors the results of a 
recent review of older women’s physical and psycholog-
ical health residing in SSA, which indicated that women 
were significantly more likely to report poor health 
compared with men.83 This finding highlights the need 
for adequate representation of both sexes in research 
studies, incorporating a gender lens in their analyses to 
understand better the unique health challenges that each 
gender faces. Further studies are also urgently needed in 
SSA to identify potential risk and protective factors, espe-
cially those that could be modified, to suggest how to best 
integrate the management of these impairments in HIV 
care guidelines in SSA. Future studies should explore the 
influence of HIV- related factors, psychosocial risk (eg, 
loneliness, ageism, stigma, social support, living arrange-
ments) and other comorbidities on the health and well- 
being of PLWH50+. To promote healthy ageing in the 
context of chronic conditions, such as HIV infection, the 
psychological and social domains are especially critical 
as they could be a way to compensate for physiological 
limitations (ie, multiple chronic conditions) and allow 
even in the context of disease and disability, to experi-
ence optimal quality of life.
Strengths and limitations
To our knowledge, this is the first comprehensive review 
of CMDs, cognitive impairment, frailty and HRQoL 
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among PLWH50 + living in SSA. Our expanded search of 
five online databases and snowballing techniques mini-
mised the risk of missing relevant studies. However, our 
review should be considered in the context of important 
limitations. Despite a thorough search strategy, some 
articles may have been missed, especially in excluding 
non- English language studies. However, these were very 
few. The substantial amount of heterogeneity across the 
studies in terms of, for example, study design, operation-
alisation of age, definitions of outcomes and measures 
made comparisons difficult and did not allow a meta- 
analysis to be done. Furthermore, most of the studies 
recruited PLWH50 + from HIV clinics whose attendees 
may represent the less- healthy end of the spectrum 
of service users leading to overestimation of reported 
outcomes. Conversely, those at the filter end of the cohort 
may be more able to attend or be proactive concerning 
their well- being, leading to underestimation of outcomes. 
Besides, the substantial methodological limitations 
observed might have biased the reported findings, hence 
limiting their external validity.
CONCLUSIONS
Overall, the existing research on the burden and deter-
minants of mental and well- being outcomes among 
PLWH50 + in SSA is scantly addressed. We also noted 
substantial limitations in many of the included studies, 
which need to be addressed in future studies. Our find-
ings underscore the need to increase the evidence base 
of these outcomes in the region. Future studies should: 
(1) explicitly target older persons ≥50 years living with 
HIV, (2) carefully select a comparison group and have 
sufficient sample sizes for adequate statistical testing, (3) 
expand the geographical distribution of these studies in 
many SSA settings and use adequately standardised survey 
tools adapted for the region and (4) generate more 
data on the risk and determinants of these outcomes 
using a gender lens. There is also an ongoing need for 
well- designed longitudinal cohort studies to study the 
temporal patterns of these outcomes in the region.
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